# Allogene Therapeutics, Inc. (ALLO)

> Source: Nexqual · https://nexqual.com/ALLO · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Allogene Therapeutics, Inc. (ALLO), nexqual.com/ALLO" · informational, not investment advice.

## ALLO major shareholder filing: Schedule 13D/A, Sep 30, 2026
TPG GP A, LLC, James G. Coulter, Jon Winkelried filed a Schedule 13D/A on Sep 30, 2026, reporting up to 0.00% of the class (more than 5% owner that may seek to influence the company). Item 4, Purpose of Transaction, quoted:

> This Amendment amends and supplements Item 4 of the Original Schedule 13D by inserting the following after the two paragraphs titled "August 2020 Distribution in Kind": "On September 28, 2026, the TPG Funds sold an aggregate of 18,716,306 shares of Common Stock at a price of $1.55 per share pursuant to Rule 144 under the Securities Act of 1933, as amended (the "September 2026 Offering")."

Source: https://www.sec.gov/Archives/edgar/data/1737287/000199937126021654/0001999371-26-021654-index.htm

**Price:** USD 1.25 (-3.85% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 1.3 · day 1.25–1.38 · 52w 1.04–4.46 · market cap $432M · NMS

## Key facts
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $134K; 3 not under a Rule 10b5-1 plan ($134K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.83 on a 1–5 scale) (12 analysts), mean target USD 9 (range 4–14).
- Total return with dividends: 1Y +7.4% vs S&P 500 +14.8%; 5Y -92.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.14, revenue estimate $2K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: ALLO paid no cash dividend in the last five years.
- Short interest: 17.11% of float (as of 2026-10-15), 9.1 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $114M | $156K | $95K | $22K | $0K | — |
| Operating income | -$180M | -$336M | -$328M | -$273M | -$209M | -$180M |
| Net income | -$182M | -$340M | -$327M | -$258M | -$191M | -$165M |
| EPS (diluted) | -$1.34 | -$2.38 | -$2.09 | -$1.32 | -$0.87 | — |
| Free cash flow | -$206M | -$226M | -$239M | -$201M | -$150M | -$103M |
| Operating margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — | — |
| Net margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — | — |
| Revenue growth | — | -99.9% | -39.1% | -76.8% | -100.0% | — |
| Cash + short-term investments | $810M | $577M | $449M | $373M | $258M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 1.0x · FCF yield -23.76% · Earnings yield -38.32%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 36,342 | $49K | 3.4% | No | Too little history (no open-market trades in 2023) |
| 2026-08-21 | Douglas Earl Martin | SVP, General Counsel | 29,697 | $63K | 5.7% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-21 | Yoshiyama Annie | SVP, Finance | 9,586 | $22K | 7.1% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.83 on a 1–5 scale), 12 analysts; mean target USD 9 (low 4, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-17 | Citizens | Reiterated | Market Outperform | $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +7.4% | -92.8% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +7.5% | -40.8% |
| Volatility (annualized) | 82.8% | 76.3% |
| Max drawdown | -60.5% (Apr 2026→Oct 2026) | -94.8% (Nov 2021→Aug 2025) |

## Dividends
ALLO paid no cash dividend in the last five years.

## Short interest
53,405,256 shares sold short, 17.11% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 59,600,117 shares (-10.4%). Days to cover: 9.1 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/ALLO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name ALLO in their own reports (relationship from ALLO's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Cellectis S.A. (CLLS) | 20-F 2026-03-20 | "We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and …" |

## Company outlook (8-K filed 2026-08-12)

- "Guidance for operating expense in 2026 is expected to be approximately $165 million."
- "GAAP Operating Expenses are expected to be approximately $225 million, including estimated non-cash stock-based compensation expense of approximately $35 million."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.14 | $-0.14 | $0.00 | $2,220 | 6 |
| Next quarter (ends 2026-12-31) | $-0.14 | $-0.15 | +$0.01 | $2,220 | 6 |
| Current fiscal year (ends 2026-12-31) | $-0.58 | $-0.61 | +$0.03 | $3.7M | 6 |
| Next fiscal year (ends 2027-12-31) | $-0.62 | $-0.68 | +$0.07 | $12.1M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±24.6%; last 8 reports averaged ±7.7%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 107.9% | ±24.6% |
| 2027-02-19 | 113 | 81.0% | ±39.8% |
| 2027-05-21 | 204 | 159.4% | ±51.1% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 12, 2026 | Quarter ended Jun 30, 2026 | −$0.13 | −$0.15 | Beat +13.3% | -6.6% |
| May 13, 2026 | Quarter ended Mar 31, 2026 | −$0.18 | −$0.18 | In line | -7.0% |
| Mar 12, 2026 | Quarter ended Dec 31, 2025 | −$0.17 | −$0.22 | Beat +22.7% | -8.7% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.19 | −$0.23 | Beat +17.4% | +6.3% |
| Aug 13, 2025 | — | — | — | — | +3.9% |
| May 13, 2025 | — | — | — | — | -18.8% |
| Mar 13, 2025 | — | — | — | — | -5.8% |
| Nov 7, 2024 | — | — | — | — | -4.3% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-27 | Schedule 13G/A | BlackRock, Inc.: 6.7% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1737287/000201238326003872/0002012383-26-003872-index.htm |
| 2026-09-30 | Schedule 13D/A | TPG GP A, LLC, James G. Coulter: 0.0% of shares, 5%+ holder that may seek to influence the company (amended) — “This Amendment amends and supplements Item 4 of the Original Schedule 13D by inserting the following after the two paragraphs titled "August 2020 Distribution in Kind": "On September 28, 2026, the TPG Funds sold an aggregate of 18,716,306 shares of Common Stock at a price of…” | https://www.sec.gov/Archives/edgar/data/1737287/000199937126021654/0001999371-26-021654-index.htm |
| 2026-09-02 | 8-K | Director or executive officer change, or pay arrangement — “(b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the "Company"), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.” | https://www.sec.gov/Archives/edgar/data/1737287/000119312526379423/0001193125-26-379423-index.htm |
| 2026-08-14 | Schedule 13G/A | Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P.: 5.6% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1737287/000123191926000912/0001231919-26-000912-index.htm |
| 2026-08-12 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/0001628280-26-056213-index.htm |
| 2026-08-12 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/0001628280-26-056198-index.htm |
| 2026-08-07 | Schedule 13G/A | Arie Belldegrun, M.D., Bellco Legacy LLC: 3.9% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1737287/000129654926000008/0001296549-26-000008-index.htm |
| 2026-08-07 | Schedule 13G | STATE STREET CORPORATION: 5.5% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1737287/000009375126000405/0000093751-26-000405-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.